Aptuit Has Been Acquired by Evotec
August 11, 2017
Aptuit, a provider of integrated early discovery to mid-phase drug development services, and a portfolio company of Welsh, Carson, Anderson & Stowe, has been acquired by Evotec for $300 million.
Cain Brothers served as a co-advisor in connection with the transaction.
Aptuit provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from their facilities in the UK, Italy, and Switzerland.
Welsh, Carson, Anderson & Stowe (WCAS) is a leading private equity firm focused exclusively on two industries: (i) healthcare and (ii) technology and technology-enabled services. WCAS has raised and managed over $22 billion in capital and has a current portfolio of approximately 25 companies.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. It operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery
For more information, please contact: